on Ottobock SE & Co. KGaA
Ottobock Achieves Record Results with Strong Growth in 2025
Ottobock SE & Co. KGaA reported substantial growth in 2025, registering a core revenue increase of 11.7% to EUR 1.6 billion. The company's underlying core EBITDA rose by nearly 30% to EUR 415 million, reflecting a margin of 26.0%. This impressive financial performance is attributed to successful strategy implementation, enhancing Ottobock's leadership in human bionics.
The company expanded its market influence by introducing innovative products like advanced knee joints and a revamped product line for arm and hand prosthetics. Strategic acquisitions in Belgium and Australia bolstered their Patient Care network. Across regions, EMEA saw growth of 12.7%, the Americas 9.5%, and APAC 7.4%.
Looking ahead, Ottobock forecasts continued robust growth in 2026, expecting a core business rise of 5.0-8.0% and further improvement in EBITDA margin. The company remains focused on long-term objectives, anticipating organic growth of 7.0-9.0% by 2029.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Ottobock SE & Co. KGaA news